Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2022-01, Vol.12 (1), p.72
• Main Authors: You, Chan-Ping, Leung, Man-Hong, Tsang, Wai-Chung, Khoo, Ui-Soon, Tsoi, Ho
• Format: Article
• Language: English
• Subjects: androgen receptor; Androgen Receptor Antagonists - therapeutic use; Androgen receptors; Antagonists; biomarker; Biomarkers; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - therapy; Cancer therapies; Chemotherapy; Clinical trials; Epidermal growth factor; ErbB-2 protein; Estrogen receptors; Female; Humans; Kinases; Neoadjuvant Therapy; Prostate; Prostate cancer; Receptor, ErbB-2 - metabolism; Receptors, Androgen - metabolism; Review; targeted therapy; Tumor suppressor genes; Tumor Suppressor Proteins - metabolism; Tumors
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom12010072

Biomarkers can be used for diagnosis, prognosis, and prediction in targeted therapy. The estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2) are standard biomarkers used in breast cancer for guiding disease treatment. The androgen receptor (AR), a nuclear hormone receptor, contributes to the development and progression of prostate tumors and other cancers. With increasing evidence to support that AR plays an essential role in breast cancer, AR has been considered a useful biomarker in breast cancer, depending on the context of breast cancer sub-types. The existing survival analyses suggest that AR acts as a tumor suppressor in ER + ve breast cancers, serving as a favorable prognostic marker. However, AR functions as a tumor promoter in ER-ve breast cancers, including HER2 + ve and triple-negative (TNBC) breast cancers, serving as a poor prognostic factor. AR has also been shown to be predictive of the potential of response to adjuvant hormonal therapy in ER + ve breast cancers and to neoadjuvant chemotherapy in TNBC. However, conflicting results do exist due to intrinsic molecular differences between tumors and the scoring method for AR positivity. Applying AR expression status to guide treatment in different breast cancer sub-types has been suggested. In the future, AR will be a feasible biomarker for breast cancer. Clinical trials using AR antagonists in breast cancer are active. Targeting AR alone or other therapeutic agents provides alternatives to existing therapy for breast cancer. Therefore, AR expression will be necessary if AR-targeted treatment is to be used.